Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma
New immunotherapy options offer high response rates for Diffuse Large B-Cell Lymphoma patients
This narrative review surveys immunotherapy options for diffuse large B-cell lymphoma beyond rituximab, including bispecific antibodies, CAR…
New immunotherapy treatments show high response rates for Diffuse Large B-Cell Lymphoma, offering hope beyond the standard 60% success rate …
Rituximab rechallenge caused severe hypersensitivity reaction in a patient with membranous nephropathy
A third Rituximab dose caused severe shock in a man with kidney disease
This case report describes a 52-year-old male with biopsy-proven primary membranous nephropathy who received a third 1 g infusion of rituxim…
A man with kidney disease developed life-threatening shock after a third Rituximab infusion, highlighting the need for careful monitoring an…
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
Case report of obinutuzumab-induced acute bicytopenia in autoimmune disease
A Common Lupus Drug Caused a Man's Platelets to Nearly Disappear
This is a case report and literature review describing a 55-year-old male with ANCA-associated glomerulonephritis who developed acute thromb…
A man with autoimmune kidney disease lost nearly all his platelets after a common cancer drug, and doctors say the warning signs were hiding…
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs.
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Narrative review links myasthenia gravis and autoimmune encephalitis risk
MG and Brain Inflammation Linked in New Review
This narrative review examines the association between myasthenia gravis and autoimmune encephalitis.
This review reveals that myasthenia gravis is often linked to brain inflammation — and that may change how doctors treat tough cases.
Sequential efgartigimod and rituximab induced improvement in three patients with refractory autoimmune encephalitis
Sequential efgartigimod and rituximab showed improvement in three patients with autoimmune encephalitis
This case series describes three patients with refractory autoimmune encephalitis treated with sequential efgartigimod and rituximab.
Three patients with difficult autoimmune encephalitis improved after sequential treatment, suggesting a potential new option for those who d…
Rituximab use in interstitial pneumonia with autoimmune features shows similar outcomes to control group
Rituximab shows similar outcomes for IPAF patients in small study
This retrospective case-control study of 14 rituximab-treated and 19 control patients with interstitial pneumonia with autoimmune features f…
A small study found that patients with a rare lung condition had similar outcomes whether they received rituximab or not, suggesting limited…
Rituximab Shows Long-Term Remission in Pediatric Steroid-Dependent Nephrotic Syndrome
Rituximab Helps Kids With Kidney Swelling
This retrospective cohort study of 42 children with steroid-dependent or frequently relapsing nephrotic syndrome found that rituximab led to…
Imagine a child who needs medicine just to stay dry.
Obinutuzumab-guided regimen achieves high remission in refractory membranous nephropathy patients
New Dosing Strategy Helps Kidney Disease Patients Who Didn’t Respond to Standard Treatment
This single-center retrospective cohort study evaluated 33 patients with refractory membranous nephropathy treated with a B-cell reconstitut…
For patients with a stubborn kidney disease who ran out of options, a smarter dosing strategy may offer a new path to recovery.